01011.HK
China NT Pharma Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.42
−1.19%Year over year
Reported trailing growth
- Revenue
- -56.8%
- EBITDA
- —
- EBIT
- +33.0%
- EPS
- +64.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -51.1%
- EBITDA
- -42.4%
- EBIT
- +6.5%
- Net income
- +51.2%
- EPS
- +78.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026